Navigation Links
BMP Sunstone's Propess(R) Recommended as First Line Treatment By the Chinese Medical Association
Date:2/27/2008

-- Recognition Substantiates Marketability of Propess(R) --

PLYMOUTH MEETING, PA., Feb. 27 (Xinhua-PRNewswire) -- BMP Sunstone Corporation (Nasdaq: BJGP) (''BMP Sunstone'' or the ''Company''), today announced that Propess(R) was recommended by the Obstetrics Group at the Obstetrics and Gynecology Branch of the Chinese Medical Association as the first line treatment for labor induction in late-stage pregnancy.

The Guidelines for Labor Induction in Late-Stage Pregnancy was published in the Chinese Journal of Obstetrics and Gynecology in January 2008. The Guidelines recommended Propess(R) as the first choice for cervical ripening, and further provided details on treatment dosage and agent-delivery.

David Gao, Chief Executive Officer of BMP Sunstone, stated, ''The recommendation of Propess(R) by the Chinese Medical Association further validates our research that Propess(R) is a leading product which should be effectively marketed to China's healthcare community. With over 421 Chinese hospitals now selling Propess(R), we have received positive feedback from doctors and will continue to educate healthcare providers about this product. Today's announcement certainly helps our cause."

BMP Sunstone started sales and marketing efforts of Propess(R) in China in 2005, after licensing the drug from its manufacturer, Cytokine PharmaSciences, Inc. (''Cytokine''). Known as Cervidil(R) in the US, Canada, Australia and New Zealand, Propess(R) is a sustained-release formulation of dinoprostone, a synthetic prostaglandin E2 used for cervical ripening in labor induction. Propess(R) is approved for use in over 50 countries around the world.

Denny Willson, President and CEO of Cytokine, stated, ''The Chinese Medical Association's recommendation that Propess(R) be the go-to product for cervical ripening strengthens our ability to educate and ultimately provide care in China. We are so pleased to work with BMP Sunstone to offer this leading product in China and we believe the demand for Propess(R) will continue to increase.''

About Cytokine PharmaSciences, Inc.

Cytokine PharmaSciences is a biopharmaceutical company located in King of Prussia (near Philadelphia), Pennsylvania. The company developed and manufactures Cervidil(R)/Propess(R), used in the obstetrics field for cervical ripening in the induction of labor. Cytokine PharmaSciences is focused on the use of polymers for the delivery of drugs to the vagina or buccal cavity, as well as the development of novel targets and therapeutic agents for the treatment of inflammation, autoimmune diseases and cancer. For more information, visit to http://www.cytokinepharmasciences.com .

About BMP Sunstone Corporation

BMP Sunstone Corporation, through its subsidiaries, is a pharmaceutical marketing and distribution company that is building a proprietary portfolio of branded pharmaceutical and healthcare products in China and is pursuing partnerships with other companies seeking to enter the Chinese pharmaceutical market. It is the only U.S. public company to offer industry partners a comprehensive suite of market-entry services in China that includes pre-market entry analysis, clinical trial management, product registration, market research, as well as pharmaceutical marketing and distribution. The Company provides distribution services for a wide range of products, including Western medicines, traditional Chinese medicines, bio-chemical medicines, medical applications, branded generic pharmaceuticals, over-the-counter healthcare products, and home healthcare supplies and equipments. BMP Sunstone's proprietary portfolio primarily focuses on the therapeutic areas of women's health and pediatrics. The Company is headquartered in Plymouth Meeting, Pennsylvania.

Safe Harbor Statement

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts, including educating healthcare providers and the future demand for Propess(R). These statements are subject to uncertainties and risks including, but not limited to, the ability to meet with healthcare providers and impact the acceptance of the product in the marketplace and other risks contained in reports filed by the Company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

For more information, please contact:

BMP Sunstone Corporation:

Fred M. Powell

Chief Financial Officer

Tel: 610-940-1675

Integrated Corporate Relations, Inc.

In the U.S.:

Ashley Ammon MacFarlane and Christine Duan

Tel: 203-682-8200

In Asia:

Xuyang Zhang

Tel: +86-10-8523-3087


'/>"/>
SOURCE BMP Sunstone Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Stop eating for two: obese moms-to-be should gain less weight than currently recommended
2. Hepatitis C Testing Recommended for Anyone with a Tattoo
3. Most With High Blood Pressure Dont Follow Recommended Diet
4. First biomarker discovered that predicts prostate cancer outcome
5. FDA Approves First Anti-Psychotic for Kids
6. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
7. First study examines newly-licensed RN work attitudes and intentions
8. Glades General Hospital First in Palm Beach County to Provide On-Site Electronic Birth Registration
9. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
10. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
11. High and mighty: first common height gene identified by researchers behind obesity gene finding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... ... 2017 , ... Each February the nation reflects upon African ... American History Month ). This month-long celebration encourages reflection upon the ... people, but also the opportunity to examine the trends of addiction among African ...
(Date:2/21/2017)... California (PRWEB) , ... February 21, 2017 , ... ... world with over 50,000 participants. The connected care demonstration spanned multiple health ... the National Coordinator, roughly 30% of providers have no Health Information Exchange outside ...
(Date:2/21/2017)... Los Angeles, CA (PRWEB) , ... February 21, 2017 , ... ... the available data on gastric balloons for weight loss. It found that the treatments ... the efforts of obese patients, when compared to unassisted efforts. It also noted very ...
(Date:2/21/2017)... ... February 21, 2017 , ... Along with Valentine’s Day, February marks American ... changes that can lead to a lifetime of heart health. In addition, it ... , The Athletic Trainers’ Society of New Jersey (ATSNJ) is urging sports ...
(Date:2/20/2017)... ... February 20, 2017 , ... MRI screening improves early diagnosis of ... from Germany published online in the journal Radiology . , MRI has ... than mammography and ultrasound. Currently, guidelines reserve breast MRI screening for women who have ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... NEW YORK , Feb. 21, 2017 /PRNewswire/ ... healthcare industry. This technique is allowing a previously ... and simplicity. Due to this ability, it is ... will cross US$ 4 Billion by 2022. The ... driven by advancements in computing platforms, rising installation ...
(Date:2/21/2017)... Feb. 21, 2017 Sangamo Therapeutics, Inc. (Nasdaq: ... that the company will release its fourth quarter and ... on Tuesday, February 28, 2017. The press release will ... ET, which will be open to the public via ... will review its financial results and provide a business ...
(Date:2/21/2017)... FALLS, Idaho , Feb. 21, 2017  International ... has completed a private placement with certain investors for ... stock of the Company, Series C Convertible Redeemable Preferred ... accrues dividends at an annual rate of 6% and ... The Company plans to use the proceeds for operating ...
Breaking Medicine Technology: